Actavis Laboratories FL Inc. asked the full Federal Circuit on Wednesday to revisit an August panel decision in a case over weight loss pill patents, citing a partial dissent by one of the panel judges who had argued the decision wrongly created a “new rule” for written description…

Read this piece in its entirety at Law360.